REPOXYGEN

Welcome to the Brand page for “REPOXYGEN”, which is offered here for Gene therapy and prophylaxis products, pharmaceutical substances and preparations, and chemical products for use in medical science, all for haematological disorders; vaccines, enzymes and enzyme preparations, pharmaceuticals for the delivery of erythropoietin genes to muscle cells, all for medical purposes; hypoxia response pharmaceutical substances and preparations, viral and retroviral vectors, viral and retroviral vector manufacturing preparations; pharmaceutical and biochemical preparations for the treatment of anaemia;rep oxygen;chemical products for use in industry and science; enzymes; chemical products for in-vitro use in laboratories and for analysis; micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles, chemical products for use in biotechnology, research and development and recombinant deoxyribonucleic acid variations thereof, all for in-vivo use;instruments and apparatus for the administration of gene therapy and prophylaxis preparations and substances, pre-filled vials; syringes and injectors for medical purposes;scientific and medical research and development; genetic engineering services, biotechnology services, licensing of intellectual property, advisory services relating to gene therapy products;.

Its status is currently believed to be active. Its class is unavailable. “REPOXYGEN” is believed to be currently owned by “Oxford BioMedica plc”.